Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring

Stock Information for Biodesix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biodesix Inc.

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026
American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification
Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers
Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
Biodesix to Participate in Upcoming Investor Conferences
Biodesix Announces Second Quarter 2026 Results and Highlights
Biodesix to Participate in Canaccord Genuity's 46th Annual Growth Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.